Impact of Diabetes Duration on Left Ventricular Mass Regression with Empagliflozin
Authors' conclusion
In the EMPA-HEART CardioLink-6 trial, empagliflozin treatment was associated with reductions in LVMi in people with T2DM and CAD irrespective of the duration of diabetes assessed categorically above and below 10 years.
Study context
- Population
- Individuals with T2DM and coronary artery disease (CAD)<10 y n = 40
- Participants
- 97 individuals
- Comparison
- Empagliflozin 10 mg daily vs placebo, by T2DM duration <10 vs ≥10 years
- Primary endpoint
- Change in LVMi (CMR), by T2DM duration
- Follow-up
- 6 months
Methodological detailsexploratory sub-analysis, placebo-controlled
- Exploratory sub-analysis
- Placebo-controlled
Primary result
As reported in the abstract
Change in LVMi by T2DM duration (subgroups)
Mean adjusted difference
−2.90 g/m²
95% CI −6.64 g/m² to 0.84 g/m²
T2DM duration <10 years
Mean adjusted difference
−3.69 g/m²
95% CI −0.14 g/m² to −7.24 g/m²
T2DM duration ≥10 years
Further findings
Baseline LVMi by T2DM duration
- Baseline LVMi by T2DM duration — No significant difference in baseline LVMi
- P = 0.11
Original publication
Impact of Diabetes Duration on Left Ventricular Mass Regression with Empagliflozin. ESC Heart Fail. Published 10 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →